Copyright © D2Hawkeye, Inc. All rights reserved Clinical applications of a medical rules-based predictive modeling system Surya Singh, M.D. Chief Medical.

Slides:



Advertisements
Similar presentations
Nursing Diagnosis: Definition
Advertisements

Chronic disease self management – a systematic review of proactive telephone applications Carly Muller Dean Schillinger Division of General Internal Medicine.
Agency for Healthcare Research and Quality (AHRQ)
Standardized Scales.
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Bill Stockdale, MBA, Celeste Beck, MPH, Lisa Hulbert, PharmD, Wu Xu, PhD Utah Department of Health Comparison with other methods of analysis: 1) Assessing.
Organization of Diabetes Care Chapter 6 Maureen Clement, Betty Harvey, Doreen M Rabi, Robert S Roscoe, Diana Sherifali Canadian Diabetes Association 2013.
Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
© 2014 American Orthotic & Prosthetic Association All rights reserved.
Plan Evaluation/Progress Monitoring Problem Identification What is the problem? Problem Analysis Why is it happening? Progress Monitoring Did it work?
Departments of Medicine and Biostatistics
99.98% of the time patients are on their own “The diabetes self-management regimen is one of the most challenging of any for chronic illness.” 0.02% of.
Elements of a clinical trial research protocol
PEBB Disease Burden Report PEBB Board of Directors August 21, 2007 Bdattach.10.
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
Multiple Criteria for Evaluating Land Cover Classification Algorithms Summary of a paper by R.S. DeFries and Jonathan Cheung-Wai Chan April, 2000 Remote.
Fundamentals of Information Systems, Second Edition
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
Short Term Load Forecasting with Expert Fuzzy-Logic System
EVIDENCE BASED MEDICINE
Chapter 17 Nursing Diagnosis
Chapter 13: Inference in Regression
Decision Support for Quality Improvement
Memorial Hermann Healthcare System Clinical Integration & Disease Management Dan Wolterman April 15, 2010.
Risk Adjustment Data For Business Insight Health Care Service Corporation September 2012.
Multiple Choice Questions for discussion
Office of Institutional Research, Planning and Assessment January 24, 2011 UNDERSTANDING THE DIAGNOSTIC GUIDE.
Reading Scientific Papers Shimae Soheilipour
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
Criteria for Assessment of Performance of Cancer Risk Prediction Models: Overview Ruth Pfeiffer Cancer Risk Prediction Workshop, May 21, 2004 Division.
An Overview of NCQA’s Relative Resource Use Measures.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Chapter 1: Research Methods
Office of MaineCare Services: Maine Accountable Communities Initiative Data Book Walk-Through May 14, 2014.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
July 31, 2009Prepared by the Maine Health Information Center Overview of All Payer Claims Data Suanne Singer, Senior Consultant Maine Health Information.
Exam Taking Kinds of Tests and Test Taking Strategies.
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
BlueCross BlueShield of Tennessee, Inc., an Independent Licensee of the BlueCross BlueShield Association. This document has been classified as public Information.
Managed Care. In the broadest terms, Kongstvedt (1997) describes managed care as a system of healthcare delivery that tries to manage the cost of healthcare,
EXPERIMENTAL EPIDEMIOLOGY
Wipanee Phupakdi, MD September 15, Overview  Define EBM  Learn steps in EBM process  Identify parts of a well-built clinical question  Discuss.
Cancer Mortality Target Measuring and Monitoring at a National Level Jennifer Benjamin, Department of Health Kathy Elliott, National Cancer Action Team.
Basic Nursing: Foundations of Skills & Concepts Chapter 9
How To Design a Clinical Trial
ASSESSING THE FEASIBILITY OF ANTIBIOTIC MANAGEMENT SERVICES THROUGH PROSPECTIVE EVALUATION ABSTRACT PURPOSE: The inappropriate and unnecessary use of antibiotics.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
Project Management “Project Planning & Scheduling” Lecture 07 Resource Person: M. Adeel Anjum.
Report Performance Monitor & Control Risk Administer Procurement MONITORING & CONTROLLING PROCESS.
Document number Anticipated Impacts for FRRS Pilot Program ERCOT TAC Meeting September 7, 2012.
Approaches to quantitative data analysis Lara Traeger, PhD Methods in Supportive Oncology Research.
Independence Plan Update February 26, © 2009 Harvard Pilgrim Health Care2 Key Points  Independence Plan introduced in 2005 –Tiered copayment product.
1 A latent information function to extend domain attributes to improve the accuracy of small-data-set forecasting Reporter : Zhao-Wei Luo Che-Jung Chang,Der-Chiang.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
CMS SAS Users Group Conference Learn more about THE POWER TO KNOW ® October 17, 2011 Medicare Payment Standardization Modeling using SAS Enterprise Miner.
Quality Measurement A Changing Landscape
Experimental Research
1st International Online BioMedical Conference (IOBMC 2015)
Presenter: Christi Melendez, RN, CPHQ
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
HR Specialty Products & Services Catalogue Executive Summary
Optum’s Role in Mycare Ohio
Chapter 2 Nursing Process
DESIGN OF EXPERIMENTS by R. C. Baker
Patient engagement with digital therapeutic leads to reduction of A1C and costs in T2DM patients: Cost savings are correlated to both A1C drops as well.
Medicaid Collaboration
Presentation transcript:

Copyright © D2Hawkeye, Inc. All rights reserved Clinical applications of a medical rules-based predictive modeling system Surya Singh, M.D. Chief Medical Officer, D2Hawkeye Adjunct Instructor of Medicine, Harvard Medical School Shiva Gautam, Ph.D. Associate Professor of Biostatistics, Harvard Medical School

page 2 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Presentation Outline  Objectives  Terminology and Structure of Medical Rules  Risk/Predictive Model Development  Analysis of “Impactable” Cost using the Risk Modeling System  Conclusions/Q and A

page 3 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Overview of D2 Medical/Clinical Rules D2 Medical/Clinical Rules Care Gaps Risk Measures/ Triggers The D2 diagnostic and procedural groupers underpin many of the rules that power our risk models

page 4 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved D2Hawkeye Medical/Clinical Rules Overview of Care Gaps and Risk Measures  Medical rules are generated in the broad categories of Care Gaps and Risk Measures.  Care Gaps are specifically focused on evaluating, both at an individual and population/cohort level, the quality and appropriateness of care being delivered.  Risk Measures are focused on identifying patients with the highest disease burden from their diagnoses, procedures, and drugs, both independently and in combination. These measures are also performed at both the individual and population/cohort level.

page 5 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved D2 Individual Level Assessment D2 Medical/Clinical Rules Care Gaps Risk Measures/ Triggers Individual Risk Index (RI) Individual Care Gap Index (CGI) ARI

page 6 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Summary of Risk Modeling System Risk IndexCare Gap Index Tag-lineThe disease burdenThe intervention opportunity What is it?A numeric score derived for each individual calculated by summing the “weight” allocated to each diagnosis, procedure (especially acute care utilization) and drug, or combination of these elements. A numeric score assigned to each individual calculated by summing the weights assigned to each care gap present. Care gaps are derived from evidence-based guidelines, the primary medical literature, standard medical practice, and the D2 Medical Advisory Board. Questions it Answers Who are our sickest members? How can we quantify the disease burden? What is the predicted cost for a given individual or group over the next 12 months? Who is missing important care opportunities? Which individuals should be targeted for intervention? What is the modifiable cost? Predicts/ Describes Heavy disease burden, likelihood of high resource utilization and high future cost over the next 12 months. Increased future health issues (and potentially acute service utilization) that can be attributed to care gaps or quality of care issues.

page 7 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Presentation Outline  Objectives  Terminology and Structure of Medical Rules  Risk/Predictive Model Development  Analysis of “Impactable” Cost using the Risk Modeling System  Conclusions/Q and A

page 8 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Risk Measure/Predictive Model Development Risk Measure Sources NCQA/HEDIS Specialty associations (e.g. ADA, ACS) Government (e.g. CMS, USPTF) Evidence-based medical practice Standard medical practice Medical literature review Specialist/expert input from Harvard/MIT medical community D2 Medical Advisory Board 1 Review of specific groups of high cost cases: – Using 3 years of data, D2 Research team performs a detailed review of events occurring prior to high cost final 12 months – From this information, new rules are generated and tested for predictive capability Collaboration with MIT operations research department allows use of advanced statistical techniques to generate additional ideas for new risk measures In particular, clustering is used to generate new ideas for risk measures 2 Separate, but related development effort to that is used for care gaps Statistically based rules from these sources are always used for predictive models and selectively used for population stratification Same as care gap sources Clinically based rules from these sources are used for population stratification and selectively for predictive models

page 9 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Examples of Risk Measures/Triggers

page 10 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Statistical Methods Overview  Rule Building: Clustering is used alongside intensive case review/auditing, primary medical literature and expert input to generate new rules for assessing risk in the population.  Rule Testing: Logistic and linear regression are used to test the predictive capability of the proposed new rules. Those with the highest performance level are included in the models. Some other rules may be used for population stratification, but not used in our predictive models.  Model Building: Statistically developed, verified and tested rules are then integrated together using D2’s proprietary engine to assign final RI scores.

page 11 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Presentation Outline  Objectives  Terminology and Structure of Medical Rules  Risk/Predictive Model Development  Analysis of “Impactable” Cost using the Risk Modeling System  Conclusions/Q and A

page 12 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Analysis of Risk Modeling System: Data Preparation  Took random sample of our normative database (220,000 from overall size of 9.5M at time of analysis)  Using 3 years of data, created two time periods:  Period 1: First 24 months (P1)  Period 2: Last 12 months (P2)  Inclusion criteria included eligibility at the end of P1

page 13 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Analysis of Risk Modeling System: RI grouping In order to examine the “impactable” cost (as measured by the Care Gap Index), we group individuals by their degree of risk (as measured by the Risk Index) as shown below: RI “Bucket” RI Range % of Individuals Average AgeCharacteristics of individuals and types of care gaps in each range %30.7 Need screening tests only %45.6 Need screening tests, some risk factor modification, and may have some chronic disease %46.5 Have chronic disease and need some recommended diagnostic testing and/or therapy %50.6 Have chronic disease, often with complications, and need more recommended diagnostic testing and/or therapy 518+4%54.9 Have chronic disease with complications, may also have some acute issues, and need more recommended diagnostic testing and/or therapy

page 14 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Overall CGI and Cost within each RI Bucket +$2200 +$1600 Complicated chronic disease (RI Bucket 4) Chronic disease (RI Bucket 3) Early chronic disease or with risk factors (RI Bucket 2) Population screening or very early disease (RI Bucket 1) Actual P2 (12 months) Mean Cost +$1300 In the example shown, we have used the difference between the CGI score C and the Base Cost to illustrate the calculation of overall “impactable” cost

page 15 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved CGI and Cost for RI Bucket 1 RI Bucket 1 Within this relatively healthy population (with a low Risk Index) that primarily requires predictable screening tests with well established economic (and clinical) benefit, the approach leads to a near linear relationship. R-squared for this relationship, without CGI grouping, is With CGI grouping, it is 0.96 Based on these findings, approximately $600 per individual per year could be saved by moving individuals to the next immediately adjacent (lower) CGI score (1-3)(4-5)(6-7)(8-10)(11+) A B C D E

page 16 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved CGI and Cost for RI Bucket 2 RI Bucket=2 (1-3)(4-7)(8-11)(12-13)(14+) A B C D E Within this moderately diseased population (with a mid-range Risk Index) that requires screening tests and some risk factor reduction, the approach leads to a near linear relationship, until we reach the upper levels of CGI (14+) R-squared for this relationship, without CGI grouping, is With CGI grouping, it is 0.52 Based on these findings, approximately $500 per individual per year could be saved by moving individuals to the next immediately adjacent (lower) CGI score

page 17 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved CGI and Cost for RI Bucket 3 (1-4)(5-8)(9-11)(12-17)(18+) RI Bucket=3 A B C D E Within this diseased population (with a mid-range Risk Index) that requires screening tests, and some monitoring and therapy, the approach again leads to a near linear relationship R-squared for this relationship, without CGI grouping, is With CGI grouping, it is 0.97 Based on these findings, approximately $600 per individual per year could be saved by moving individuals to the next immediately adjacent (lower) CGI score

page 18 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved CGI and Cost for RI Bucket 4 RI Bucket=4 (1-4)(5-9)(10-14)(15-20)(21+) A B C D E Within this diseased population (with a upper to mid-range Risk Index) that often have complications and require additional monitoring and therapy, there is more inconsistency and a less linear relationship R-squared for this relationship, without CGI grouping, is With CGI grouping, it is 0.56 Based on these findings, approximately $700 per individual per year could be saved by moving individuals to the next immediately adjacent (lower) CGI score

page 19 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Conclusions  Our work to date demonstrates that there is a quantifiable cost associated with care gaps that exist in a commercially insured population  The estimated value of these gaps has been evaluated over a 12 month period  The value of closing care gaps depends on the population segment, as the relative proportion of different care gap types (screening, chronic disease diagnosis and monitoring, chronic disease therapy) varies  Additional study is needed to evaluate a longer follow-up time period (24 or 36 months) and to specifically track the performance of individual patients and cohorts as they move between CGI scores Thanks for your time and attention!

page 20 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Appendix

page 21 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Key Findings from Risk Model Analysis 1)The D2 Longitudinal Database has been rigorously evaluated for group level cost prediction (size now 11M). 2)The Risk Index (RI) predicts PMPY cost (over the next 12 months) with high accuracy for large groups. 3)We have now defined the short term (next 12 months) amount of potentially “impactable” cost for various segments of the patient population

page 22 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Key Finding 1: RI Group Level Prediction  Divided the random sample of the norm dataset into 2 halves  Used a linear regression model to evaluate the association between average P2 cost and RI for the first half (D2 Norm A )  Used regression coefficients from this to predict P2 cost for the second half (D2 Norm B ) and compared this prediction with the actual observed values, producing:  R 2 = 0.88  Mean Absolute Prediction Error (MAPE) = 43%

page 23 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Key Finding 1: RI’s Group Level Prediction is Accurate Risk Index P2 Cost ($PMPY) RI’s group level prediction, with groups defined by their RI score, is accurate: R2 = 0.88 Mean Absolute Prediction Error (MAPE) = 43% RI Group Level Prediction based on RI-defined Groups

page 24 Confidential and Proprietary Copyright © D2Hawkeye, Inc. All rights reserved Key Finding 2: RI’s Group Level Prediction using “Real-World” Employer Groups Risk Index P2 Cost ($PMPY) The slopes of the two regression lines displayed are within 7% of each other Comparison of Groups defined by RI and “Real-World” Employer Groups